A Python library for post-quantum cryptography. Contribute to alraddady/alkindi development by creating an account on GitHub.

Dunia Arab juga telah melahirkan musisi-musisi besar.

Le 22 mai, une soixantaine de collégiens et lycéens ont participé à la finale du concours de cryptographie Alkindi. L’occasion d’initier les élèves au chiffrement et déchiffrement de messages et peut-...

Am 22.09.2025 wurde vom Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) gemeldet, dass es aktuell auch beim Arzneimittel ALKINDI 5 MG GRANULAT ZUR ENTNAHME AUS KAPSEL - OP50 Lieferengpässe gibt. Wieso es derzeit zu Einschränkungen kommt und wofür das Arzneimittel gebraucht wird,...

Plusieurs voix de gauche dénoncent le silence de Bruno Retailleau après le meurtre d’un fidèle dans une mosquée du Gard, près d’Alès.

Eton Pharmaceuticals (Nasdaq: ETON) reported that a new formulation of KHINDIVI (hydrocortisone) oral solution demonstrated bioequivalence to ALKINDI SPRINKLE, the FDA‑approved hydrocortisone granule formulation. Based on these data, Eton has submitted a Prior Approval Supplement (PAS) to the U.S. FDA seeking to expand KHINDIVI’s label to include younger pediatric adrenal insufficiency patients, below the current approval for ages five years and older.According to Eton, the PAS could support a potential expanded indication decision in the first half of 2027. KHINDIVI is currently the only FDA‑approved oral hydrocortisone solution and carries extensive safety warnings, including risks of adrenal crisis, systemic adverse reactions from inactive ingredients, growth retardation, Cushing’s syndrome, decreased bone mineral density, psychiatric, ophthalmic, and gastrointestinal adverse reactions.

Eton Pharmaceuticals (ETON) has received FDA approval for KHINDIVI™, the first and only FDA-approved hydrocortisone oral solution for pediatric patients aged 5+ with adrenocortical insufficiency. The 1mg/ml solution offers precise dosing without the need to split tablets, requiring no refrigeration or mixing. Commercial launch is expected by June 2nd, with distribution through Anovo specialty pharmacy. KHINDIVI complements Eton's existing ALKINDI SPRINKLE® product line, with the company projecting combined peak sales exceeding $50 million. The U.S. market includes over 5,000 potential patients aged 5-17. The Eton Cares Program will provide prescription support and $0 co-pays for qualifying patients.

Plan de Sauvegarde de l’Emploi chez LDLC, un antivol innovant pour vélo qui dégage ;une odeur de cadavre....